Komori
Shin Nippon Biomedical Laboratories (2395) · RiskRestated

Risk of Trial Subjects Suffering Health Damage and Related Liability

First written in FY2016. 14 of 16 entries say "Restated". Latest entry: FY2026-H1.

16entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2024-Q3MitigatedFY20242016: 120162017: 120172018: 020182019: 120192020: 420202021: 220212022: 220222023: 220232024: 220242025: 12025
Same theme, other companies
Health-damage and product-liability risks involving pharmaceuticalsA theme 60 companies write about · 69 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.

37 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 60 companies compared. The sentences above are computed from all 60.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「No new business or other risks arose during the current interim consolidated accounting period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  2. FY2024MitigatedAnnual report

    「医薬品の安全性情報について、国内チームだけでなく、グローバル(PPD)の部門とも協働しながら、世界中の医薬品に関する情報を集積し、分析・評価し、適切な安全対策をとることによって、健康被害が生じるリスクの軽減に努めております。」

    治験被験者の健康被害リスクに対し、GCP準拠に加えてPPDのグローバル部門との安全性情報の集積・分析・評価と対策を行う体制を具体化している。
  3. FY2024-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  4. FY2024-Q2RestatedAnnual report

    「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  5. FY2024-Q1RestatedAnnual report

    「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  6. FY2023-Q2RestatedAnnual report

    「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  7. FY2022-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  8. FY2021RestatedAnnual report

    「また、係る訴訟が社会問題に発展した場合には、当社グループの信用が損なわれ、当社グループの財政状態及び経営成績に影響を及ぼす可能性があります。」

    治験被験者の健康被害が当社の過失に起因する場合の損害賠償・信用低下リスクを継続している。
  9. FY2021-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  10. FY2021-Q2RestatedAnnual report

    「During the second quarter of the current consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  11. FY2021-Q1RestatedAnnual report

    「During the first quarter of the current consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  12. FY2020RestatedAnnual report

    「また、係る訴訟が社会問題に発展した場合には、当社グループの信用が損なわれ、当社グループの財政状態及び経営成績に影響を及ぼす可能性があります。」

    治験被験者の健康被害が当社の過失に起因する場合の損害賠償・信用低下リスクを継続して記載している。
  13. FY2020-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  14. FY2020-Q2RestatedAnnual report

    「During the second quarter of the current consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    治験被験者の健康被害・賠償リスクについて、重要な変更がないと記載している。
  15. FY2017RestatedAnnual report

    「また、係る訴訟が社会問題に発展した場合には、当社グループの信用が損なわれ、当社グループの財政状態及び経営成績に影響を及ぼす可能性があります。」

    治験被験者の健康被害が当社の過失に起因する場合の損害賠償・信用低下リスクを引き続き記載している。
  16. FY2016First statedAnnual report

    「また、係る訴訟が社会問題に発展した場合には、当社グループの信用が損なわれ、当社グループの財政状態及び経営成績に影響を及ぼす可能性があります。」

    被験者の健康被害が当社の過失に起因する場合の損害賠償請求や信用低下を想定している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Shin Nippon Biomedical Laboratories's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.